Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H24FN5O4 |
| Molecular Weight | 441.4555 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC(OC)=C1)N2CCN(CC2)C(=O)NC3=NC4=CC(F)=CC=C4N=C3OC
InChI
InChIKey=KAKPGJJRYRYSTP-UHFFFAOYSA-N
InChI=1S/C22H24FN5O4/c1-30-16-11-15(12-17(13-16)31-2)27-6-8-28(9-7-27)22(29)26-20-21(32-3)25-18-5-4-14(23)10-19(18)24-20/h4-5,10-13H,6-9H2,1-3H3,(H,24,26,29)
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C113293
Created by
admin on Sat Dec 16 11:36:05 GMT 2023 , Edited by admin on Sat Dec 16 11:36:05 GMT 2023
|
PRIMARY | NCIT | ||
|
888478-45-3
Created by
admin on Sat Dec 16 11:36:05 GMT 2023 , Edited by admin on Sat Dec 16 11:36:05 GMT 2023
|
PRIMARY | |||
|
11619093
Created by
admin on Sat Dec 16 11:36:05 GMT 2023 , Edited by admin on Sat Dec 16 11:36:05 GMT 2023
|
PRIMARY | |||
|
ZU8OM8V5WF
Created by
admin on Sat Dec 16 11:36:05 GMT 2023 , Edited by admin on Sat Dec 16 11:36:05 GMT 2023
|
PRIMARY | |||
|
SUPINOXIN
Created by
admin on Sat Dec 16 11:36:05 GMT 2023 , Edited by admin on Sat Dec 16 11:36:05 GMT 2023
|
PRIMARY | Description: Supinoxin, also known as RX-5902, is orally bioavailable small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68), with potential anti-proliferative and antineoplastic activity. Upon oral administration, P-p68 inhibitor RX-5902 may both inhibit the activity of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein and facilitate the induction of cyclin-dependent kinase inhibitor 1 (p21). This may prevent G2/M cell cycle progression and lead to growth inhibition in tumor cells. P-p68 is overexpressed in various types of solid tumors but absent in normal tissues, and plays a role in tumor progression and metastasis. (last updated: 5/1/2016) |
ACTIVE MOIETY
